Carbon metabolism as a drug target in Leishmania

Héctor Acosta, Meng Yuan, Ana J. Cáceres, Wilfredo A. Quiñones, Juan Luis Concepción, Paul A.M. Michels

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Several pathways of carbon metabolism, or parts of them, play important roles in the proliferation and virulence of the human pathogenic stage of Leishmania, the intracellular amastigotes. Kinetic and structural properties of a considerable number of enzymes from this metabolic network from Leishmania spp. and/or related Trypanosoma spp. have been studied in detail and compared with the enzymes catalysing the corresponding reactions in human. This has allowed the identification of parasite-enzyme-specific features. Potent and selective inhibitors of the trypanosomatid enzymes have been developed to exploit these unique properties. Some of these compounds stunt the proliferation of parasites, including the intracellular Leishmania amastigotes, without affecting growth of host cell lines, and/or affect their virulence in infected animal models.

Original languageEnglish
Title of host publicationDrug Discovery for Leishmaniasis
EditorsCarmen Gil, Luis Rivas
Place of PublicationCroydon, UK
PublisherRoyal Society of Chemistry
Chapter15
Pages297-315
Number of pages19
Volume60
ISBN (Electronic)978-1-78801-258-4
ISBN (Print)978-1-78262-889-7
DOIs
Publication statusPublished - 1 Jan 2018

Publication series

NameRSC Drug Discovery Series
Number60
Volume2018-January
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

Fingerprint Dive into the research topics of 'Carbon metabolism as a drug target in Leishmania'. Together they form a unique fingerprint.

Cite this